SCHEMBL17830735

SCHEMBL17830735

O=C(Cn1c(=O)oc2cc(Cl)ccc21)OCc1cccc([N+](=O)[O-])c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 1/20 0.48
IDO1 P14902 2/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
POLB P06746 2/20 0.46
MAPT P10636 1/20 0.46
LMNA P02545 2/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830734 0.89 IDO1 (0.52) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830725 0.88 POLB (0.52) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830736 0.86 MIF (0.52) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830715 0.85 PIK3CB (0.54) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830720 0.84 TP53 (0.56) CCR2IDO1USP2ALDH1A1POLB
SCHEMBL17830723 0.84 PKM (0.53) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830724 0.82 IDO1 (0.51) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830729 0.82 CYP1A2 (0.45) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830733 0.79 MAPT (0.46) IDO1USP2ALDH1A1POLBMAPT
SCHEMBL17830721 0.79 TP53 (0.59) CCR2USP2ALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A CCR2 2294/4885IDO1 1644/4885USP2 2467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.